FDA expands approval of Imfinzi to reduce risk of non-small cell lung cancer progressing
The FDA approved AstraZeneca's Imfinzi (durvalumab) for treatment of patients with stage III non-small cell lung cancer hose tumors are not able to be surgically removed and whose cancer has not progressed after treatment with chemotherapy and radiation. February 16, 2018